Notable Labs Ltd (NTBL) Short-Term Debt to Equity

Notable Labs, Ltd. (NTBL) management is implementing personalized therapy regimens to combat severe tumors. This price action on GURU.Markets is currently fixed at 0.00, which is attributed to a lack of stable cash flows due to the early stage of IT service development. High R&D expenditures and stringent FDA oversight, combined with protection via the PPMP system, create significant barriers to entry.

NTBL - Notable Labs Ltd Short-Term Debt to Equity Ratio over the range 02/21/2024 - 11/02/2024

Financial and market metric breakdowns for notablelabs.com (NTBL)

- stock quotes and analyst forecast:
Stock Price Notable Labs Inc.|NTBL - Analyst Consensus Forecast
- market capitalization details:
Market Value Notable Labs Ltd|NTBL - Business Value
- balance sheet equity data:
Book Value per Share Notable Labs|NTBL - Company Net Assets|Market Capitalization to Book Value Ratio notablelabs.com|NTBL - Company Assets
- business debt structure and liquidity details:
Debt to Equity Notable Labs, Ltd.|NTBL - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Notable Labs|NTBL - Aggregate Debt Obligations|Debts to Book Capitalization Notable Labs Ltd|NTBL - Company Long-Term Liabilities|Company Current Liabilities Notable Labs|Quick Liquidity notablelabs.com
- earnings and market ratios statistics:
NTBL - Final Profit
Fundamental valuation:Notable Labs Inc.

For Notable Labs, Ltd. (NTBL), which develops AI-driven live-cell screening in the B2B oncology diagnostics sector, the short-term debt-to-equity ratio reflects the dependence of operational stability on borrowed funds with maturities exceeding one year. This metric measures the proportion of long-term liabilities within the capital structure, where an increasing ratio signals heightened financial leverage and potential liquidity risks for the investor.

Competitors of Notable Labs, Ltd.

Short-Term Debt to Capital ONC|Short-Term Debt to Capital Halozyme Corp (HALO)|Short-Term Debt to Equity Revolution Medicines RVMD|AAPG: Short-Term Debt to Capital Ratio|CG Oncology - Short-Term Debt to Capital|UroGen Pharma Ltd (URGN) - Short-Term Debt to Equity Ratio|BCAX: Short-Term Debt to Capital|Current Liabilities to Capital Personalis Genomics (PSNL)|Short-Term Debt to Equity Erasca, Inc.|DCTH: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio YMAB (Y-mAbs Therapeutics, Inc.)|AURA (Aura Biosciences Inc) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital CADL (Candel Therapeutics, Inc.)|ARAY - Short-Term Debt to Equity Ratio|SLS: Short-Term Debt to Equity Ratio|ACTU - Short-Term Debt to Capital|Citius Oncology (CTOR) - Short-Term Debt to Equity|TuHURA Biosciences - Ratio of Short-Term Indebtedness to Capital|TARA (Protara) - Short-Term Debt to Capital|Current Liabilities to Capital Fate Pharma FATE|Short-Term Debt to Equity Aadi Bioscience Inc (WHWK)|tscan.com - Short-Term Debt to Capital Ratio|Short-Term Debt to Equity Champions Oncology, Inc. CSBR|XBiotech Inc (XBIT) - Current Liabilities to Capital|CVM: Short-Term Debt to Equity Ratio|OS Therapies, Inc. - Short-Term Loans to Capital Ratio|RADX: Short-Term Debt to Capital|Artiva Biotherapeutics (ARTV) - Short-Term Debt to Capital|ANL (Adlai Nortye Ltd) - Short-Term Debt to Capital|Short-Term Debt to Equity VERU|Short-Term Debt to Equity Tempest Tx (TPST)|Short-Term Debt to Equity XLO (xiliotx.com)|Short-Term Debt to Capital RENB (Renovaro)|Mural Oncology PLC (MURA) - Current Liabilities to Capital|KAPA: Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital OKUR (OnKure Therapeutics Inc)|w2.cytomed.sg (GDTC) - Short-Term Debt to Equity|CRIS (Curis) - Short-Term Debt to Equity|APLM (Apollomics Inc.) - Short-Term Debt to Capital|Short-Term Debt to Capital tharimmune.com|Short-Term Debt to Capital ADVB|Short-Term Debt to Equity GNPX (Genprex Inc.)|Short-Term Debt to Equity Calidi Biotherapeutics, Inc. CLDI|Short-Term Debt to Capital Coefficient sunshinebiopharma.com (SBFM)|XBIO: Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital SLRX (salariuspharma.com)|Purple Biotech Ltd. (PPBT) - Short-Term Debt to Equity|AONC (American Oncology Network, Inc.) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio BGNE|CKPT (Checkpoint Therapeutics Inc) - Short-Term Loans to Capital Ratio|Short-Term Debt to Capital ELEV|icadmed.com - Short-Term Debt to Capital Ratio|Ikena Oncology - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital Coefficient Viracta Therapeutics Inc. (VIRX)|MOR - Short-Term Debt to Equity|NAYA (NAYA Biosciences Corp) - Short-Term Debt to Capital Ratio|AAPGV (Ascentage Pharma Group) - Short-Term Debt to Equity Ratio